Picture of Xvivo Perfusion AB logo

XVIVO — Xvivo Perfusion AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareSpeculativeMid CapFalling Star

Brief: Xvivo Gets Approval From Swedish MPA To Begin Clinical Studies With New Products

May 15 (Reuters) - Xvivo Perfusion AB  XVIVO.ST :
    * XVIVO HAS RECEIVED APPROVAL FROM THE SWEDISH MPA TO BEGIN
CLINICAL STUDIES WITH THE COMPANY'S NEW PRODUCTS FOR HEART
PRESERVATION
    * STUDY CAN BE STARTED IN SWEDEN
    * APPLICATIONS TO OTHER EU COUNTRIES THAT WILL PARTICIPATE
IN
STUDY CAN BE SUBMITTED TO NATIONAL ETHICS COMMITTEES.

Source text for Eikon:  ID:nWkr3ZTzlX 
Further company coverage:  XVIVO.ST 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))

Recent news on Xvivo Perfusion AB

See all news